Merus NV (NASDAQ:MRUS)
| 16.27 Delayed Data As of May 19 |  +0.41 / +2.59%Today’s Change | 14.78 Today|||52-Week Range 33.09 | -48.84% Year-to-Date |
Latest MRUS News | Press Releases
| Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates May 09 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 15.81 |
| Today’s open | 16.05 |
| Day’s range | 15.51 - 16.35 |
| Volume | 156,207 |
| Average volume (3 months) | 193,701 |
| Market cap | $695.5M |
Data as of 4:03pm ET, 05/19/2022
Growth & Valuation
| Earnings growth (last year) | +40.84% |
| Earnings growth (this year) | -53.49% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +64.00% |
| P/E ratio | NM |
| Price/Sales | 25.02 |
| Price/Book | 2.20 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| NSTGNanoString Technolog... | +0.99 | +6.62% |
| REPLReplimune Group Inc | +0.15 | +1.05% |
| NKTRNektar Therapeutics | +0.11 | +2.89% |
| CDMOAvid Bioservices Inc | +0.86 | +7.39% |
Data as of 4:03pm ET, 05/19/2022
Financials
| Next reporting date | August 12, 2022 |
| EPS forecast (this quarter) | -$0.58 |
| Annual revenue (last year) | $49.1M |
| Annual profit (last year) | -$66.8M |
| Net profit margin | -136.06% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Utrecht, Utrecht |
Forecasts
